Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TARS Stock Summary
Top 10 Correlated ETFs
TARS
In the News
Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
TARS has reported positive results from three clinical trials of lotilaner in various formulations. TARS plans to discuss the path forward in these new indications with the US Food and Drug Administration. TARS has also reported sales of $13.1M from the first full quarter of Xdemvy's launch as a treatment for Demodex blepharitis.
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%
The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Tarsus Pharmaceuticals, Inc. (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tarsus to Participate at Upcoming Investor Conferences
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will participate in the following conferences:
Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy
Does Tarsus Pharmaceuticals, Inc. (TARS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 5 a.m. PT / 8 a.m. ET on Tuesday, February 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.
Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?
Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Tarsus Pharmaceuticals: 3 Clinical Catalysts In The Next 4 Months, Xdemvy Launch Underway
TARS has launched a new drug, Xdemvy, for the treatment of Demodex blepharitis, with net product sales of $1.7M in the first five weeks following launch. TARS has readouts from three clinical trials due in the next four months, with one due in Q4'23. TARS completed a follow-on offering in August, raising net proceeds of $99.4M. TARS had $246.9M in cash at the end of Q3'23.
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants David Nakasone - Head, IR Bobak Azamian - Chairman, CEO Aziz Mottiwala - CCO Jeff Farrow - CFO, CSO Conference Call Participants Jason Gerberry - Bank of America Eddie Hickman - Guggenheim Securities Oren Livnat - H.C. Wainwright Frank Brisebois - Oppenheimer Operator Good afternoon and welcome to the Tarsus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call.
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, November 9, 2023 to report its third quarter 2023 financial results and provide a corporate update.
Rare Stock Picks In September 2023 - From 32 Discerning Analysts
Welcome to another installment of our monthly Rare Buy article where we highlight September investment picks you may have missed. As you know some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come by in today's market environment. Featured in this series are investment ideas published in the last month from analysts who have made ONLY 1 Buy/Strong Buy stock recommendation in the past three months.
TARS Financial details
TARS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 2.77 | 1.05 | 0.59 | |
Net income per share | -1.98 | -4.32 | -0.67 | -2.52 | -4.62 | |
Operating cash flow per share | -1.55 | -3.41 | 0.18 | -1.99 | -4 | |
Free cash flow per share | -1.63 | -3.48 | 0.15 | -2.01 | -4.19 | |
Cash per share | 24.53 | 27.09 | 8.36 | 8.82 | 7.74 | |
Book value per share | -2.54 | 26.74 | 8.11 | 7.84 | 6.7 | |
Tangible book value per share | -2.54 | 26.74 | 8.11 | 7.84 | 6.57 | |
Share holders equity per share | -2.54 | 26.74 | 8.11 | 7.84 | 6.7 | |
Interest debt per share | 0.09 | 0.16 | 0.09 | 0.91 | 1.14 | |
Market cap | 48.63M | 256.55M | 462.47M | 360.92M | 595.01M | |
Enterprise value | -9.16M | 89.25M | 293.03M | 309.42M | 401.8M | |
P/E ratio | -10.41 | -9.57 | -33.45 | -5.81 | -4.38 | |
Price to sales ratio | 0 | 0 | 8.11 | 13.98 | 34.1 | |
POCF ratio | -13.24 | -12.14 | 123.39 | -7.36 | -5.06 | |
PFCF ratio | -12.64 | -11.88 | 146.26 | -7.29 | -4.84 | |
P/B Ratio | -8.1 | 1.55 | 2.77 | 1.87 | 3.02 | |
PTB ratio | -8.1 | 1.55 | 2.77 | 1.87 | 3.02 | |
EV to sales | 0 | 0 | 5.14 | 11.99 | 23.03 | |
Enterprise value over EBITDA | 2.33 | -3.32 | -27.7 | -5.23 | -2.82 | |
EV to operating cash flow | 2.49 | -4.22 | 78.18 | -6.31 | -3.42 | |
EV to free cash flow | 2.38 | -4.13 | 92.67 | -6.25 | -3.27 | |
Earnings yield | -0.1 | -0.1 | -0.03 | -0.17 | -0.23 | |
Free cash flow yield | -0.08 | -0.08 | 0.01 | -0.14 | -0.21 | |
Debt to equity | -0.03 | 0.01 | 0.01 | 0.1 | 0.15 | |
Debt to assets | 0 | 0 | 0.01 | 0.09 | 0.11 | |
Net debt to EBITDA | 14.7 | 6.22 | 16.02 | 0.87 | 1.36 | |
Current ratio | 70.85 | 31.68 | 15.33 | 14.61 | 6.93 | |
Interest coverage | -107.45 | -143.61 | 0 | -28.52 | -42.78 | |
Income quality | 0.79 | 0.79 | -0.27 | 0.79 | 0.86 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0.45 | 1.74 | 0 | |
Research and developement to revenue | 0 | 0 | 0.73 | 1.65 | 2.88 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0.01 | |
Capex to operating cash flow | 0.05 | 0.02 | -0.16 | 0.01 | 0.05 | |
Capex to revenue | 0 | 0 | -0.01 | -0.02 | -0.32 | |
Capex to depreciation | -4.73 | -4.75 | -1.88 | -1.56 | -6.27 | |
Stock based compensation to revenue | 0 | 0 | 0.15 | 0.52 | 1.14 | |
Graham number | 10.63 | 50.98 | 11.08 | 21.09 | 26.41 | |
ROIC | 0.76 | -0.16 | -0.07 | -0.29 | -0.63 | |
Return on tangible assets | -0.08 | -0.16 | -0.08 | -0.27 | -0.52 | |
Graham Net | -2.68 | 26.12 | 7.77 | 7.6 | 5.89 | |
Working capital | 57.21M | 165.27M | 164.47M | 209.95M | 219.19M | |
Tangible asset value | -6.01M | 165.98M | 166.73M | 192.9M | 193.12M | |
Net current asset value | -6.29M | 164.66M | 163.78M | 190.41M | 186.89M | |
Invested capital | -0.03 | 0.01 | 0.01 | 0.1 | 0.15 | |
Average receivables | 20K | 28K | 56K | 1.84M | 10.65M | |
Average payables | 315.5K | 1.35M | 5.46M | 9.3M | 14.03M | |
Average inventory | 10K | 10K | 0 | 2.38M | 3.93M | |
Days sales outstanding | 0 | 0 | 0.59 | 50.64 | 370.59 | |
Days payables outstanding | 2.25K | 3.32K | 1.53K | 3.79K | 4.16K | |
Days of inventory on hand | 98.65 | 0 | 0 | 1.82K | 711.9 | |
Receivables turnover | 0 | 0 | 619.86 | 7.21 | 0.98 | |
Payables turnover | 0.16 | 0.11 | 0.24 | 0.1 | 0.09 | |
Inventory turnover | 3.7 | 0 | 0 | 0.2 | 0.51 | |
ROE | 0.78 | -0.16 | -0.08 | -0.32 | -0.69 | |
Capex per share | -0.07 | -0.07 | -0.03 | -0.02 | -0.19 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.41 | 0.09 | 0.57 | 0.06 | 0.41 | |
Net income per share | -0.53 | -0.82 | -1.17 | -1.28 | -1.31 | |
Operating cash flow per share | -0.44 | -0.83 | -0.89 | -1.06 | -1.23 | |
Free cash flow per share | -0.45 | -0.84 | -0.92 | -1.2 | -1.11 | |
Cash per share | 8.82 | 7.56 | 6.65 | 8.06 | 7.12 | |
Book value per share | 7.84 | 6.52 | 5.51 | 6.98 | 6.17 | |
Tangible book value per share | 7.84 | 6.52 | 5.51 | 6.85 | 6.05 | |
Share holders equity per share | 7.84 | 6.52 | 5.51 | 6.98 | 6.17 | |
Interest debt per share | 0.85 | 0.97 | 0.96 | 0.96 | 0.98 | |
Market cap | 360.92M | 334.52M | 484.56M | 544.16M | 646.87M | |
Enterprise value | 309.42M | 293.04M | 402.83M | 347.62M | 453.66M | |
P/E ratio | -6.9 | -3.82 | -3.86 | -3.48 | -3.86 | |
Price to sales ratio | 36.09 | 133.81 | 31.72 | 290.84 | 49.47 | |
POCF ratio | -33.19 | -15.23 | -20.34 | -16.81 | -16.45 | |
PFCF ratio | -32.81 | -14.99 | -19.69 | -14.81 | -18.31 | |
P/B Ratio | 1.87 | 1.93 | 3.28 | 2.55 | 3.28 | |
PTB ratio | 1.87 | 1.93 | 3.28 | 2.55 | 3.28 | |
EV to sales | 30.94 | 117.22 | 26.37 | 185.79 | 34.69 | |
Enterprise value over EBITDA | -23.83 | -12.94 | -13.22 | -8.49 | -10.29 | |
EV to operating cash flow | -28.46 | -13.34 | -16.91 | -10.74 | -11.53 | |
EV to free cash flow | -28.13 | -13.13 | -16.37 | -9.46 | -12.84 | |
Earnings yield | -0.04 | -0.07 | -0.06 | -0.07 | -0.06 | |
Free cash flow yield | -0.03 | -0.07 | -0.05 | -0.07 | -0.05 | |
Debt to equity | 0.1 | 0.15 | 0.17 | 0.14 | 0.15 | |
Debt to assets | 0.09 | 0.12 | 0.13 | 0.11 | 0.11 | |
Net debt to EBITDA | 3.97 | 1.83 | 2.68 | 4.8 | 4.38 | |
Current ratio | 14.61 | 15.74 | 12.43 | 11.15 | 6.93 | |
Interest coverage | -21.76 | -36.48 | -40.27 | 47.71 | -44.94 | |
Income quality | 0.8 | 0.94 | 0.76 | 0.83 | 0.94 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.46 | 6.04 | 1.33 | 16.21 | 5.02 | |
Research and developement to revenue | 1 | 4.94 | 0.82 | 6.47 | 1.02 | |
Intangibles to total assets | 0 | 0 | 0 | 0.01 | 0.01 | |
Capex to operating cash flow | 0.01 | 0.02 | 0.03 | 0.14 | -0.1 | |
Capex to revenue | -0.01 | -0.14 | -0.05 | -2.34 | 0.31 | |
Capex to depreciation | -1.3 | -3.27 | -4.32 | -17.93 | 11.53 | |
Stock based compensation to revenue | 0.37 | 1.56 | 0.34 | 2.81 | 0.42 | |
Graham number | 9.68 | 10.98 | 12.05 | 14.17 | 13.49 | |
ROIC | -0.07 | -0.12 | -0.03 | -0.16 | -0.34 | |
Return on tangible assets | -0.06 | -0.1 | -0.17 | -0.15 | -0.16 | |
Graham Net | 7.5 | 6.21 | 5.12 | 6.43 | 5.42 | |
Working capital | 209.95M | 195.39M | 168.71M | 236.03M | 219.19M | |
Tangible asset value | 192.9M | 173.4M | 147.73M | 209.7M | 193.12M | |
Net current asset value | 190.41M | 170.84M | 142.28M | 204.61M | 186.89M | |
Invested capital | 0.1 | 0.15 | 0.17 | 0.14 | 0.15 | |
Average receivables | 3.8M | 3.25M | 1.58M | 3.31M | 12.04M | |
Average payables | 7.75M | 9.48M | 8.61M | 9.28M | 14.27M | |
Average inventory | 0 | -209K | -209K | 7.5K | 1.56M | |
Days sales outstanding | 32.24 | 105.05 | 1.45 | 306.41 | 121.92 | |
Days payables outstanding | 2.23K | 3.19K | 2.33K | 2.48K | 1.34K | |
Days of inventory on hand | 0 | -147.53 | 0 | 3.58 | 229.96 | |
Receivables turnover | 2.79 | 0.86 | 62.1 | 0.29 | 0.74 | |
Payables turnover | 0.04 | 0.03 | 0.04 | 0.04 | 0.07 | |
Inventory turnover | 0 | -0.61 | 0 | 25.13 | 0.39 | |
ROE | -0.07 | -0.13 | -0.21 | -0.18 | -0.21 | |
Capex per share | -0.01 | -0.01 | -0.03 | -0.14 | 0.13 |
TARS Frequently Asked Questions
What is Tarsus Pharmaceuticals, Inc. stock symbol ?
Tarsus Pharmaceuticals, Inc. is a US stock , located in Irvine of Ca and trading under the symbol TARS
What is Tarsus Pharmaceuticals, Inc. stock quote today ?
Tarsus Pharmaceuticals, Inc. stock price is $36.95 today.
Is Tarsus Pharmaceuticals, Inc. stock public?
Yes, Tarsus Pharmaceuticals, Inc. is a publicly traded company.